Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)

Market Cap	380.16M -7.9%
Revenue (ttm)	200.11M +2.2%
Net Income	25.45M -19.3%
EPS	0.61 -19.3%
Shares Out	n/a
PE Ratio	14.94
Forward PE	n/a
Dividend	0.32 (3.52%)
Ex-Dividend Date	Mar 30, 2026

Volume	200
Average Volume	115
Open	9.16
Previous Close	n/a
Day's Range	9.16 - 9.16
52-Week Range	9.16 - 12.57
Beta	-0.44
RSI	n/a
Earnings Date	May 8, 2026

About SBLOF

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1957
• Employees: 1,532
• Stock Exchange: OTCMKTS
• Ticker Symbol: SBLOF

Financial Performance

In fiscal year 2025, SBLOF's revenue was 32.41 billion, an increase of 22.54% compared to the previous year's 26.45 billion. Earnings were 4.92 billion, a decrease of -10.97%.

Financial numbers in JPY